GlassScriptPhysician profile
Lynndoh Valmores
NPI 1265903116
$10,177.47
in general payments reported to CMS, 2019-2025
25 companies · $2,522 in 2025
The $2,522 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,188 · 2022: $2,285 · 2023: $1,542 · 2024: $2,641 · 2025: $2,522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,448 · Education: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,448.21 |
| Education | $256.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,730.46 | 2021-2025 | |
| Janssen Biotech, INC. | $1,580.46 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $1,135.91 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,127.44 | 2021-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $620.67 | 2022-2025 | Nemluvio |
| Incyte Corporation | $450.55 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $412.38 | 2021-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $290.12 | 2023-2024 | Vtama |
| Pfizer INC. | $285.25 | 2022-2025 | |
| Biofrontera INC. | $245.61 | 2022-2025 | Ameluz |
| Ucb, INC. | $208.24 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $199.22 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Kyowa Kirin, INC. | $125.45 | 2021-2025 | Poteligeo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $121.56 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $113.92 | 2022-2023 | Sotyktu |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $101.04 | 2022-2025 | |
| Allergan, INC. | $98.11 | 2022 | |
| Amgen INC. | $72.52 | 2024-2025 | Otezla, Otezla |
| Organon LLC | $69.84 | 2023-2025 | Hadlima, Vtama |
| Arcutis Biotherapeutics, INC. | $56.79 | 2024-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $52.91 | 2022-2024 | |
| Surgenex LLC | $26.63 | 2025 | Surmatrix, Pellograft, Renograft |
| Mylan Institutional INC. | $19.63 | 2023 | Hulio |
| Almirall LLC | $17.22 | 2025 | Klisyri |
| Kowa Pharmaceuticals America, INC. | $15.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynndoh Valmores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.